title: Assessment of telavancin minimal inhibitory concentrations by revised broth microdilution method in phase 3 complicated skin and skin-structure infection clinical trial isolates.
abstract: The broth microdilution (BMD) MIC testing method for telavancin was recently revised BMD (rBMD) to improve accuracy and reproducibility. Staphylococcus aureus isolates from telavancin phase 3 complicated skin and skin-structure infection (cSSSI) studies were tested using the rBMD method. Retesting of 1132 isolates produced MICs ranging from ≤0.015 to 0.12μg/mL that were 8-fold lower than the original method. All isolates tested remained susceptible to telavancin at the revised susceptibility breakpoint of 0.12μg/mL. The clinical cure and microbiological eradication rates were 90% (368/409) and 89% (366/409) for telavancin-treated patients, and were similar for patients with methicillin-susceptible and -resistant S. aureus isolates and S. aureus isolates with elevated vancomycin MICs (≥1μg/mL). The data presented here are aimed to update the literature and better inform clinicians and clinical microbiologists about the revised telavancin MICs, as well as the corresponding clinical and microbiological cure rates for cSSSI patients.
authors.affiliation: Theravance Biopharma US, Inc., South San Francisco, CA, USA. Electronic address: jsmart@smartmicrobiology.com.
authors.forename: Jennifer I
authors.initials: JI
authors.lastname: Smart
authors.affiliation: Duke Clinical Research Institute and Duke University Medical Center, Durham, NC, USA.
authors.forename: G Ralph
authors.initials: GR
authors.lastname: Corey
authors.affiliation: Department of Medicine, Section of Infectious Diseases, Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno (CEMIC), Buenos Aires, Argentina.
authors.forename: Martin E
authors.initials: ME
authors.lastname: Stryjewski
authors.affiliation: Theravance Biopharma US, Inc., South San Francisco, CA, USA.
authors.forename: Whedy
authors.initials: W
authors.lastname: Wang
authors.affiliation: Theravance Biopharma US, Inc., South San Francisco, CA, USA.
authors.forename: Steven L
authors.initials: SL
authors.lastname: Barriere
mesh_terms: D000617:Aminoglycosides / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D006801:Humans; D000077427:Lipoglycopeptides; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects* / Q000302:isolation & purification; D008826:Microbial Sensitivity Tests; D013207:Staphylococcal Skin Infections / Q000188:drug therapy* / Q000382:microbiology; D014640:Vancomycin / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D000077427:Lipoglycopeptides; D014640:Vancomycin; C487637:telavancin
keywords: Complicated skin and skin-structure infection; Lipoglycopeptide; S. aureus; Telavancin